Completed cases

Complaints considered by the Code of Practice Panel are judged on the evidence provided by both parties. Once concluded a case report is published on this website. Good compliance decisions rely on both the interpretation of the Code and an understanding of its application, published case reports help in this regard and set precedent in a particular set of circumstances. When making decisions on compliance with the Code, knowledge gained from previous case reports can be beneficial.                        

Search options for completed cases can be found below, please scroll down.

Please note that abbreviations/acronyms can only be searched under the Text search.

Where searching under clause number please look under sub clause where one exists, eg Clause 6.1 not just 6.

Click on the blue arrow below to search completed cases.  Searches can be run by free Text, Case number, Respondent, Complainant or Clause Number.

The results can then be filtered by: Year Received or Applicable Code Year. Results will be automatically ordered by 'Completed Date - Most Recent First', other options are available to select. 

The order of the results displayed can be changed by clicking in the box beside 'Order Results By'.

Please Note:

Cases can only link to clauses in the interactive 2019 or 2016 Codes.

 

 

 

Search completed cases

Sunovion Pharmaceuticals Europe voluntarily admitted a breach of the Code in relation to its failure to disclose support to patient organisations as required by the Code and the provision of inaccurate information to the PMCPA. As Paragraph 5.6 of the Constitution and Procedure required the Director to treat a voluntary admission as a complaint, the matter was taken up with Sunovion. Sunovion admitted that in its comments on the PMCPA audit report in relation to Case AUTH/2935/2/17...

Applicable Code: 2016

Received: 16 March 2018

Completed: 11 July 2019

An anonymous, ex-employee of Sunovion alleged that a regional business manager (RBM) encouraged staff to pressurise customers into prescribing Latuda (lurasidone) for schizophrenia by suggesting that if Latuda was not considered as part of a patient review, they might be sued by patients or patient groups.  It was alleged that the RBM also encouraged staff to quote national guidelines which stated that a medication review should be considered if a patient had side-effects.  The complainant...

Applicable Code: 2016

Received: 13 February 2017

Completed: 11 July 2019

  Otsuka Pharmaceuticals Europe, voluntarily admitted that it might have breached the Code with regard to updates to the Jinarc (tolvaptan) summary of product characteristics (SPC).  Jinarc was used in certain patients with chronic kidney disease. As Paragraph 5.6 of the Constitution and Procedure required the Director to treat a voluntary admission as a complaint, the matter was taken up with Otsuka Europe. Otsuka Europe explained that there had been two parallel revisions to the Jinarc SPC since...

Applicable Code: 2016

Received: 12 March 2019

Completed: 05 July 2019

  An anonymous, non-contactable individual who described themselves as a recent employee at Otsuka complained about material used at two overseas meetings.  The complainant submitted that he/she had reported the matters at issue but as nothing had happened, decided to complain to the Authority. The first matter concerned an alleged out-of-date advertisement that was used in association with a congress in France held in March 2018 (European Psychiatric Association (EPA)) which the complainant alleged was non-compliant. Secondly, the...

Applicable Code: 2016

Received: 30 January 2019

Completed: 05 July 2019

A complainant who described him/herself as a concerned UK health professional, complained about a number of companies’ websites including that of AstraZeneca UK.  The pages at issue concerned Forxiga (dapagliflozin), Onglyza (saxagliptin) and Symbicort (budesonide/formoterol).  Forxiga and Onglyza were used in certain patients with type 2 diabetes mellitus and Symbicort was used in certain patients with asthma or chronic obstructive pulmonary disease (COPD). The detailed response from AstraZeneca appears below. 1 Forxiga The complainant alleged that significant space was given...

Applicable Code: 2016

Received: 29 October 2018

Completed: 05 July 2019

No Summary as outwith the scope of the Code

No breach Clause(s): Outwith the scope of the Code

Applicable Code: 2016

Received: 12 September 2018

Completed: 03 July 2019

No summary, outwith the scope of the Code

No breach Clause(s): Outwith the scope of the Code

Applicable Code: 2016

Received: 12 September 2018

Completed: 03 July 2019

No summary as outwith the scope of the Code

No breach Clause(s): Outwith the scope of the Code

Applicable Code: 2016

Received: 12 September 2018

Completed: 03 July 2019

No summary, outwith the scope of the Code

No breach Clause(s): Outwith the scope of the Code

Applicable Code: 2016

Received: 12 September 2018

Completed: 03 July 2019

No summary, outwith the scope of the Code

No breach Clause(s): Outwith the scope of the Code

Applicable Code: 2016

Received: 12 September 2018

Completed: 03 July 2019

About 1212 result(s)